While left ventricular (LV) structure and function differ between hypertensive women and men, it remains unclear whether sex affects regression of LV hypertrophy with antihypertensive treatment. We analysed paired echocardiograms in 500 men and 347 women enrolled in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study at baseline and after 12 months of antihypertensive treatment with either losartan or atenolol. At enrolment, 177 women and 242 men were randomized to losartan-based treatment and 161 women and 247 men were randomized to atenolol-based treatment (sex difference ¼ NS). After 12 months of antihypertensive treatment, blood pressure was lowered similarly in women (152/83 from 174/97 mmHg) and men (149/85 from 173/99 mmHg; both Po0.001, sex difference ¼ NS), without significant change in body weight in either sex. Cardiac output and pulse pressure/stroke volume were equivalently reduced in both sexes (À0.2 vs À0.1 l/min and both -0.20 mmHg/ml/m 2 , respectively; both P ¼ NS). Absolute LV mass change after 12 months of antihypertensive treatment was greater in men than in women (À30 vs À24 g, P ¼ 0.01). However, after adjusting for baseline LV mass and randomized study treatment, LV mass reduction was greater in women than in men (À33 vs À23 g, P ¼ 0.001). LV mass regression was greater in women, by 8.072.8 g, after adjusting for baseline LV mass and randomized study treatment. After consideration of baseline LV mass and randomized study treatment, antihypertensive treatment regressed LV hypertrophy more in women. Further studies are needed to identify the mechanisms and prognostic implications of this sex-related difference.
While left ventricular (LV) structure and function differ between hypertensive women and men, it remains unclear whether sex affects regression of LV hypertrophy with antihypertensive treatment. We analysed paired echocardiograms in 500 men and 347 women enrolled in the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study at baseline and after 12 months of antihypertensive treatment with either losartan or atenolol. At enrolment, 177 women and 242 men were randomized to losartan-based treatment and 161 women and 247 men were randomized to atenolol-based treatment (sex difference ¼ NS). After 12 months of antihypertensive treatment, blood pressure was lowered similarly in women (152/83 from 174/97 mmHg) and men (149/85 from 173/99 mmHg; both Po0.001, sex difference ¼ NS), without significant change in body weight in either sex. Cardiac output and pulse pressure/stroke volume were equivalently reduced in both sexes (À0.2 vs À0.1 l/min and both -0.20 mmHg/ml/m 2 , respectively; both P ¼ NS). Absolute LV mass change after 12 months of antihypertensive treatment was greater in men than in women (À30 vs À24 g, P ¼ 0.01). However, after adjusting for baseline LV mass and randomized study treatment, LV mass reduction was greater in women than in men (À33 vs À23 g, P ¼ 0.001).
Introduction
Left ventricular (LV) hypertrophy is an independent predictor of increased cardiovascular morbidity and mortality in patients with hypertension 1, 2 or coronary artery disease 3 and in the general population. 4 Several studies have identified sex-related differences in the response to chronic pressure overload, with men having higher LV mass than women. 5, 6 Furthermore, in Framingham subjects with isolated systolic hypertension, men had more eccentric LV hypertrophy while women had more concentric hypertrophy, 6 possibly accounting for better preserved LV ejection fraction in women with pressure overload. [7] [8] [9] Several studies have shown that most antihypertensive medications can regress LV hypertrophy, though perhaps with varying efficacy. [10] [11] [12] However, it remains unclear whether regression of LV hypertrophy differs between sexes. Thus, the present study was undertaken to determine whether sexrelated differences in LV mass regression exist in the participants of the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study after 12 months of sustained antihypertensive treatment.
Methods

Subjects
The LIFE echocardiography substudy enrolled 960 patients with Stage I-III hypertension, approximately 11% of the overall 9193 LIFE patients. 13, 14 The study was carried out as part of a multicentre study with echocardiography centres in Denmark, Finland, Iceland, Norway, Sweden, the United Kingdom, and the United States. Ethics committees or institutional review boards of the participating institutions approved the study, and all patients enrolled gave written informed consent. For inclusion in the LIFE study, a screening electrocardiogram must have demonstrated LV hypertrophy by Cornell voltage-duration criteria ((SV3 þ RaVL [ þ 6 mm in women]) Â QRS 42 440 mm Â ms) or Sokolow-Lyon voltage criteria (SV1 þ RV5/RV6 438 mm). 13, 14 Patients with known significant aortic stenosis (mean pressure gradient 420 mmHg), heart failure or LV ejection fraction o40%, or significant valvular regurgitation were excluded from the study. After a run-in period that documented eligible levels of clinic blood pressure during 1479 days of placebo treatment, subjects underwent baseline echocardiography. 15 Arterial blood pressure was also measured by an arm cuff sphygmomanometer at the end of the echocardiogram, after subjects had been resting supine in a dimly lit room for approximately 30 min. Patients with severe (3 þ or 4 þ ) aortic or mitral regurgitation were excluded from the present analysis.
Echocardiographic methods
Studies were performed using commercially available echocardiographs equipped with 3.0-3.5 MHz and 2.0-2.5 MHz transducers with M-mode, 2-D and pulsed, continuous and colour-flow Doppler capabilities, and using a protocol developed for use in multicentre studies. [15] [16] [17] [18] The parasternal acoustic window was used to record X10 consecutive beats of 2-D and M-mode recordings of the LV internal diameter and wall thicknesses at or just below the tips of the mitral valve leaflets in long-and shortaxis views. Additional M-mode, 2-D, and Doppler recordings were performed as previously described. [16] [17] [18] Studies were sent to Cornell Medical Center Echocardiography Reading Center for blinded interpretation by experienced technician and physician readers.
Echocardiographic measurements
Correct orientation of planes for imaging and Doppler recordings was verified by standard procedures. 16, 19, 20 Measurements were made using a computerized review station with a digitizing tablet and monitor screen overlay for the calibration and performance of each needed measurement. Enddiastolic and end-systolic LV internal dimensions and ventricular septal and posterior wall thicknesses were measured by American Society of Echocardiography (ASE) recommendations 19 on up to three cycles. When optimal LV orientation could not be obtained by M-mode, correctly oriented 2-D linear dimensions were measured by the ASE leading-edge convention. 20 End-diastolic ASE LV dimensions were used to calculate LV mass by a formula that yields values closely related (r ¼ 0.90, Po0.001) to necropsy LV weight, 21 which showed excellent reproducibility (intraclass correlation coefficient ¼ 0.93, Po0.001) between separate echocardiograms in 183 hypertensive patients. 22 LV mass was considered as an unadjusted variable. Relative wall thickness (RWT) was calculated as end-diastolic posterior wall thickness/LV internal radius. 23 Stroke volume was calculated by the invasively validated aortic annular leading-edge method as (aortic annular cross-sectional area) Â (Doppler time velocity integral of aortic annular flow), 24 and used to calculate cardiac output and total peripheral resistance. The pulse pressure/stroke volume ratio was used as an indirect measure of systemic arterial stiffness. 25 
Data handling and statistical analyses
Data management and analysis were performed using SPSS 11.0 (SPSS, Chicago, IL, USA) software. Data are presented as mean 7 SD for continuous variables and as proportions for categorical variables. Differences in clinical and echocardiographic variables at baseline and after 1 year of antihypertensive treatment within sex were assessed by the paired t-test for repeated measurements. Betweensex differences in clinical and echocardiographic variables were assessed by analysis of covariance. A general factorial model was used for analysis of covariance, and multiple simple contrasts were obtained after adjustment of the confidence intervals with Sidak's method to compare LV hypertrophy regression between sexes after adjustment for baseline LV mass and for randomized treatment allocation to losartan-or atenolol-based therapy. Two-tailed Po0.05 indicated statistical significance.
Results
Baseline and 12-month clinical features of LIFE men and women
Of the 960 LIFE echocardiography substudy participants, 21(2.2%) did not have baseline LV mass measurements; 77(8%) did not have 12-month echocardiograms because of death, infirmity, or failure to cooperate; and 15(1.6%) had immeasurable LV mass at 12 months. Compared to patients included in the present report (n ¼ 847), those who were ineligible were older (6977 vs 6677 years, Po0.001), had faster heart rates (70712 vs 67712 bpm, P ¼ 0.04), lower haemoglobin (14.071.4 vs 14.371.3 g/dl, P ¼ 0.046), and were more likely to be diabetic (14 vs 10%, Po0.05) and African-American (25 vs 13%, P ¼ 0.01), without difference in sex, blood pressure, body mass index, and serum glucose, creatinine, and cholesterol levels.
At the time of screening for the LIFE study, 79 (23%) women and 133 (27%) men were not receiving antihypertensive medications, whereas 69 (22%) and 128 (31%) were receiving angiotensin converting enzyme inhibitors, 95 (30%) and 121 (29%) were receiving b-blockers, 111 (35%) and 175 (42%) were receiving calcium channel blockers, and 106 (33%) and 131 (32%) were receiving diuretics; 61 (6.5%) women were on hormone replacement therapy at the time of screening. At enrolment, 177 women and 242 men were randomized to losartan-based treatment and 161 women and 247 men were randomized to atenolol-based treatment (P ¼ NS).
As may be seen in Table 1 , body weight did not change significantly from baseline to 12 months of antihypertensive treatment. Women had lower hemoglobin and serum creatinine levels than men at baseline without sex differences in serum glucose. Serum glucose and creatinine levels rose during 12 months of treatment. There was no sex-related difference in change over 12 months in any variable in Table 1 .
As expected, after 12 months of antihypertensive treatment, systolic and diastolic blood pressure and pulse pressure were substantially lower in both men and women, with no between-sex difference in blood pressure change. Heart rate fell equivalently in both sexes. Similarly, 12-month changes in stroke volume, cardiac output, peripheral resistance, and systemic arterial stiffness, as estimated by the pulse pressure/stroke volume ratio, did not differ significantly between sexes (Table 2) .
Baseline and 12-month LV geometric features of LIFE men and women Table 3 shows baseline and 12-month LV geometric measurements by sex. Absolute LV mass reduction was greater in men than in women by about 6 g at 12 months (Figure 1, left panel) , while RWT reduction was identical in both sexes. Mean absolute LV mass change was identical in women with or without hormone replacement therapy (both À24733 g).
Because LV mass was the only variable identified in the univariate analyses that differed at baseline 26 between sexes and was associated with the change in LV mass during 12 months of antihypertensive treatment (Table 3) , change in LV mass was adjusted for effects of baseline LV mass and randomized study treatment (Figure 1, right panel) . Analysis of covariance, by the general linear model, revealed that the reduction of LV mass from baseline to 12 Sex-related difference in LVH regression JN Bella et al months was positively related to female sex (P ¼ 0.001), independent of associations with higher baseline LV mass (Po0.001) and treatment allocation to losartan-or atenolol-based regimens. LV mass fell by 8.072.8 g more in women than in men in analysis of covariance. Additional adjustment for gender differences in antihypertensive medications used prior to enrolment in the study slightly increased the mean difference between women and men in the adjusted reduction of LV mass, to 11.8 g.
Discussion
Previous studies have identified sex-related differences in cardiac structure and function, with men having higher LV mass 5 and worse systolic [7] [8] [9] and diastolic function 27, 28 than women. Our study is the first to demonstrate that sex also influences regression of LV hypertrophy in a large sample of hypertensive patients with a high prevalence of LV hypertrophy at baseline who were treated in a systematic fashion by structured, blinded drug regimens. After adjustment for the important effects of baseline LV mass 11 and randomized study treatment, 14 LIFE women had greater reductions in LV mass than LIFE men after 12 months, by 8.0 g (about 6% more).
Female sex and clinical variables
The Treatment of Mild Hypertension Study (TOMHS) has shown that lifestyle change, including weight reduction, low-sodium intake, and exercise, had salutary effects on LV hypertrophy. 10 . After 12 months, in which all TOMHS participants received nutritional-hygienic treatment, there was no additional significant difference with regard to LV hypertrophy regression between the group that received low doses of active antihypertensive medications as opposed to placebo, with no significant interaction of treatment with sex. 10 Among LIFE patients, there was no systematic change in body weight in either sex between baseline and 12 months of follow-up. Similarly, Schmieder et al. 29 showed in a meta-analysis of high-quality clinical trials that both systolic and diastolic blood pressure reductions were independent correlates of LV mass regression. Among LIFE patients, the degree of systolic and diastolic blood pressure reduction was equivalent in women and men. Thus, factors other than weight loss and blood pressure control could be responsible for the observed sex-related difference in LV mass reduction in the LIFE study. Heart rate, peripheral resistance, and the pulse pressure/ stroke volume ratio also fell similarly in LIFE women and men, thereby not providing evidence of other haemodynamic explanations for the sexrelated difference in LV hypertrophy regression observed in the present study.
Female sex and LV hypertrophy
Several studies have documented sex-related differences in adaptation to chronic pressure overload, [6] [7] [8] with women having a tendency towards concentric geometry (ie, increased RWT). We have recently shown in a smaller study that hypertensive patients with concentric LV geometry had greater LV mass reduction after 12 months of antihypertensive therapy than those with normal LV geometry or Sex-related difference in LVH regression JN Bella et al eccentric LV hypertrophy. 30 Among LIFE patients, there was no difference in LV geometry between sexes. 26 Furthermore, there were identical reductions in RWT in both sexes from baseline to after 12 months of antihypertensive treatment. Thus, the sex-related difference in LV hypertrophy regression observed in LIFE patients cannot be attributed to differences in cardiac geometry between sexes at baseline.
Potential mechanisms
At the present time, the mechanisms underlying the observed sex-related difference in regression of LV hypertrophy are uncertain. While experimental studies in animals have demonstrated sex-related differences in LV systolic function and biochemistry induced by castration or hormone replacement 31, 32 and that cardiac myocytes contain functional oestrogen receptors, 33 our study in patients 455 years of age indicates that hormone replacement therapy was not a factor in the observed sex-related difference in LV hypertrophy regression because the degree in absolute LV mass change was identical in women with or without hormone replacement. Further studies are needed to clarify the role of hormone replacement on LV hypertrophy.
In older adults with aortic stenosis and LV hypertrophy, aortic valve replacement was more effective in regression of cardiac hypertrophy in women than in men. 34 Myocardial biopsy indicated that men had a greater degree of myocardial fibrosis than women. Unfortunately, myocardial biopsies were not obtained in LIFE patients, and serum carboxy-terminal propeptide of procollagen type I levels 35 were only assessed in a local substudy, making it impossible to determine whether or not sex-related differences in myocardial fibrosis existed in the present study population.
Study limitations
Our study was conducted in older adults with moderate-to-severe hypertension and electrocardiographic LV hypertrophy enrolled in the LIFE study, and thus may not be applicable to the general population.
Clinical implications
The present study indicates that after 12 months of antihypertensive treatment with losartan-or atenolol-based treatment, women had greater reduction in LV mass than men. While most antihypertensive agents regress LV hypertrophy, though perhaps with varying efficacy, [10] [11] [12] the choice of antihypertensive agent to best regress LV hypertrophy in men, as opposed to women, may be crucial. Recent studies have indicated that angiotensin converting enzyme inhibitors (lisinopril) and angiotensin receptor blockers (losartan) decreased myocardial fibrosis in hypertensive patients more than diuretics (hydrochlorothiazide) or calcium channel blockers (amlodipine). 36, 37 The LIFE trial has provided evidence that losartan-based antihypertensive therapy is more effective than a traditional regimen based on atenolol with regard to both regression of LV hypertrophy and prognosis.
14 Assignment to losartan-or atenolol-based regimens had no impact on the greater regression of LV hypertrophy in LIFE women as compared to LIFE men revealed by multivariate analyses. In addition, the more frequent use of angiotensin converting enzyme inhibitors in men than in women and for other gender imbalances in antihypertensive treatment prior to enrolment in the LIFE study may have resulted in slight augmentation of the greater adjusted reduction in LV mass in women during the first year of randomized treatment in the LIFE trial. Further studies are needed to identify mechanisms underlying the sexrelated difference in regression of LV hypertrophy and its impact on prognosis.
